Saturday 17 October 2026
Export IFRX’s income statement to Excel — free account
InflaRx N.V.
IFRX Healthcare Biotechnology
In the quarter to June 2026, revenue fell 128.9%, EPS grew 54.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
1.32
0.12
−8.33%
Follow IFRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
440.26 | 2,220.94 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(8.04) | (16.27) | — | — | |
P/B ratio |
1.71 | 1.45 | — | — | |
Price to Tangible BV |
1.71 | 1.45 | — | — | |
EV/Sales |
150.90 | 411.26 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(0.65) | (0.31) | — | — | |
EV/FCF |
(0.64) | (0.31) | — | — | |
Quick Ratio |
2.78 | 3.88 | 3.88 | 8.10 | |
Current Ratio |
3.33 | 4.13 | 4.16 | 8.22 | |
Net Debt/EBITDA |
5.15 | 3.28 | 5.77 | 22.35 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.34 | 1.32 | 0.24 | |
Capex/Depreciation |
(0.83) | 0.02 | (0.11) | (0.50) | |
Interest Coverage |
(696.76) | (870.88) | (504.43) | (500.48) | |
Research and Development Expense of Revenue |
26,146.59% | (15,830.20%) | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15,871.68% | (10,522.34%) | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2,929.75% | (349.24%) | 0.00% | 0.00% | |
Graham Net Nets |
0.56 | 0.67 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(50.75%) | (75.25%) | — | — | |
Free Cash Flow Yield |
(53.18%) | (59.16%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.17) | (0.06) | (0.12) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.06) | (0.12) | (0.03) | |
Cash per Share |
0.88 | 0.82 | 0.69 | 1.60 | |
Shareholders Equity per Share |
0.78 | 0.70 | 0.60 | 1.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.78 | 0.70 | 0.60 | 1.44 | |
Free Cash Flow |
(11.40) | (4.17) | (8.66) | (2.99) | |
Working Capital |
51.92 | 45.99 | 42.14 | 168.90 | |
Capital Expenditures |
(0.10) | 0.00 | (0.01) | (0.05) | |
Net Current Asset Value |
51.05 | 45.23 | 41.43 | 168.21 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
3.72 | 0.05 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
2.41 | 1.75 | 1.86 | 1.90 | |
Average Payables |
11.84 | 9.22 | 7.24 | 8.61 | |
Average Inventory |
8.31 | — | — | — | |
Average Assets |
81.89 | 72.37 | 74.44 | 138.72 | |
Average Common Equity |
62.41 | 56.74 | 58.71 | 117.36 |
Columns are period end dates